FDA panel rejects experimental weight loss pill

Thu, 07/15/2010 - 18:21 EDT
 

By MATTHEW PERRONE
2010-07-15T22:21:51Z
GAITHERSBURG, MD. (AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight....

Related

  • Vivus weight loss drug faces safety questions (AP)

    Vivus Inc.'s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week.

  • Vivus weight loss drug faces safety questions (AP)

    AP - Vivus Inc.'s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week.

  • Vivus weight loss drug faces safety questions (AP)

    AP - Vivus Inc.'s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week.

  • Vivus weight loss drug faces safety questions (AP)

    Vivus Inc.'s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week.

  • US panel approves French morning-after pill

    A US health panel Thursday voted unanimously to allow the sale of a controversial French birth control pill, which can prevent pregnancy for up to five days after unprotected sex.The final decision by the Food and Drug Administration (FDA) is not expected for several months, but the so-called morning-after pill "Ella" got the nod of approval by 11 medical experts on an FDA advisory panel who deemed it safe.

  • Vivus's Obesity Drug Raises Familiar Questions

    Derek Lowe submits: One big story from last week was the FDA advisory panel's "No" decision on Qnexa, the drug-combo obesity therapy developed by Vivus (

  • FDA experts say new "morning after" pill safe, efficient

    A new "morning after" pill that can be taken up to five days after a sexual encounter is safe, efficient, and presents no unexpected side effects, US regulatory staff said in a report out Tuesday.The report from Food and Drug Administration (FDA) staff comes ahead of a Thursday review by a panel that will issue a recommendation on approving the drug ulipristal -- produced by French pharmaceutical HRA Pharma -- for sale in the United States.The FDA usually follows the panel's advice.

  • FDA panel OKs Crestor cholesterol pill's wider use

    GAITHERSBURG, Md. (AP) -- Federal health advisers say expanded use of AstraZeneca's cholesterol pill Crestor can benefit patients with healthy cholesterol levels by preventing heart attack, stroke and death....

  • Vivus weight loss drug faces safety questions

    By 2010-07-13T12:00:23Z NEW YORK (AP) -- Vivus Inc.'s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week....

  • US health experts advise against new obesity drug

    A panel of experts advising the US Food and Drug Administration voted Thursday against approving for sale a new obesity treatment called Qnexa, citing safety risks.The FDA is not required to follow the recommendation of the expert panel on endocrinological and metabolic drugs, but generally accepts its findings.Qnexa, made by California-based biotech firm Vivus, is the first obesity drug submitted to the FDA in a decade.

 
DJI: 10419.63 0.96% |S&P 500: 1101.49 1.03% |FTSE: 5428.15 1.05% |Nikk.: 9114.13 0.56% |DAX: 6134.62 0.83% |HSI: 20971.50 0.49% |
FX: EUR/GBP: 1.1987 | USD/EUR: 1.2896 | JPY/USD: 84.435 | Commodities: Gold: 1247.55 | Crude - CLH09.NYM: 0.00 |